Additionally, the distribution of the mutations in DNMT3A is more diverse in T-ALL, with the prevalence of mutations affecting the R882 “hot spot” accounting for less than 20%, compared to over 40% in AML [41,43]. This evidence concerns the gene DNMT3A and acute lymphoblastic leukemia.